AYTU (Aytu BioPharma) Other Net Income (Loss) : $0.38 Mil (TTM As of Sep. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Aytu BioPharma Other Net Income (Loss)?

Aytu BioPharma's Other Net Income (Loss) for the three months ended in Sep. 2024 was $0.38 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 was $0.38 Mil.

Aytu BioPharma's quarterly Other Net Income (Loss) stayed the same from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) but then increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.38 Mil).

Aytu BioPharma's annual Other Net Income (Loss) stayed the same from Jun. 2022 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) but then increased from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($0.00 Mil).

Aytu BioPharma Other Net Income (Loss) Historical Data

The historical data trend for Aytu BioPharma's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Other Net Income (Loss) Chart

Aytu BioPharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Other Net Income (Loss)

Get a 7-Day Free Trial

Aytu BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Net Income (Loss)	Get a 7-Day Free Trial															-0.65	-	-	-	0.38

Aytu BioPharma Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.38 Mil.

Aytu BioPharma Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (NAS:AYTU) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

0A8M:UK

Address

7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website

https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Executives

Christopher Brooke	officer: Chief Operating Officer	C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Jarrett Disbrow	officer: Chief Business Officer	373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
John Jr. Donofrio	director	C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Carl Dockery	director	P.O. BOX 2477, LAKELAND FL 33806-2477
Vivian H Liu	director
Mark K Oki	officer: Chief Financial Officer	C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Joshua R. Disbrow	director, officer: Chief Executive Officer	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Abhinav Jain	director	C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Wilmot B. Harkey	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Greg Pyszczymuka	officer: Chief Commerical Officer	C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gerald W. Mclaughlin	director	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Beth Hecht	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050